Potential of resveratrol in the treatment of systemic lupus erythematosus (Review).

IF 3.4 3区 医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL Molecular medicine reports Pub Date : 2024-10-01 Epub Date: 2024-08-19 DOI:10.3892/mmr.2024.13306
Rongxiu Huo, Yanting Yang, Xiaocong Huo, Danli Meng, Rongjun Huang, Yang Yang, Jinying Lin, Yijia Huang, Xia Zhu, Chengcheng Wei, Xinxiang Huang
{"title":"Potential of resveratrol in the treatment of systemic lupus erythematosus (Review).","authors":"Rongxiu Huo, Yanting Yang, Xiaocong Huo, Danli Meng, Rongjun Huang, Yang Yang, Jinying Lin, Yijia Huang, Xia Zhu, Chengcheng Wei, Xinxiang Huang","doi":"10.3892/mmr.2024.13306","DOIUrl":null,"url":null,"abstract":"<p><p>Systemic lupus erythematosus (SLE) is a multi‑system chronic autoimmune disease with a complex occurrence and development process, associated with immune disorders, uncertain prognosis, and treatment modalities which vary by patient and disease activity. At present, the clinical treatment of SLE mainly focuses on hormones and immunosuppressants. In recent years, the research on new treatment strategies for SLE has been booming, and strong preclinical results and clinical research have promoted the development of numerous drugs (such as rituximab and orencia), but numerous of these drugs have failed to achieve effectiveness in clinical trials, and there are some adverse reactions. Recent evidence suggests that resveratrol (RSV) has the effect of ameliorating immune disorders by inhibiting overactivation of immune cells. In the present review, advances in research on the protective effects and potential mechanisms of RSV against SLE are summarized and the potential potency of RSV and its use as a promising therapeutic option for the treatment of SLE are highlighted.</p>","PeriodicalId":18818,"journal":{"name":"Molecular medicine reports","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11350626/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular medicine reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3892/mmr.2024.13306","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/19 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Systemic lupus erythematosus (SLE) is a multi‑system chronic autoimmune disease with a complex occurrence and development process, associated with immune disorders, uncertain prognosis, and treatment modalities which vary by patient and disease activity. At present, the clinical treatment of SLE mainly focuses on hormones and immunosuppressants. In recent years, the research on new treatment strategies for SLE has been booming, and strong preclinical results and clinical research have promoted the development of numerous drugs (such as rituximab and orencia), but numerous of these drugs have failed to achieve effectiveness in clinical trials, and there are some adverse reactions. Recent evidence suggests that resveratrol (RSV) has the effect of ameliorating immune disorders by inhibiting overactivation of immune cells. In the present review, advances in research on the protective effects and potential mechanisms of RSV against SLE are summarized and the potential potency of RSV and its use as a promising therapeutic option for the treatment of SLE are highlighted.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
白藜芦醇治疗系统性红斑狼疮的潜力(综述)。
系统性红斑狼疮(SLE)是一种多系统慢性自身免疫性疾病,其发生和发展过程复杂,伴有免疫功能紊乱,预后不确定,治疗方式因患者和疾病活动性而异。目前,系统性红斑狼疮的临床治疗主要以激素和免疫抑制剂为主。近年来,有关系统性红斑狼疮新治疗策略的研究方兴未艾,强大的临床前研究成果和临床研究推动了众多药物(如利妥昔单抗和奥伦西亚)的开发,但这些药物中的许多在临床试验中未能取得疗效,而且还存在一些不良反应。最近的证据表明,白藜芦醇(RSV)通过抑制免疫细胞的过度激活,具有改善免疫紊乱的作用。在本综述中,总结了白藜芦醇对系统性红斑狼疮的保护作用和潜在机制的研究进展,并强调了白藜芦醇的潜在功效及其作为治疗系统性红斑狼疮的一种有前途的治疗选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Molecular medicine reports
Molecular medicine reports 医学-病理学
CiteScore
7.60
自引率
0.00%
发文量
321
审稿时长
1.5 months
期刊介绍: Molecular Medicine Reports is a monthly, peer-reviewed journal available in print and online, that includes studies devoted to molecular medicine, underscoring aspects including pharmacology, pathology, genetics, neurosciences, infectious diseases, molecular cardiology and molecular surgery. In vitro and in vivo studies of experimental model systems pertaining to the mechanisms of a variety of diseases offer researchers the necessary tools and knowledge with which to aid the diagnosis and treatment of human diseases.
期刊最新文献
[Corrigendum] MicroRNA‑378 enhances migration and invasion in cervical cancer by directly targeting autophagy‑related protein 12. [Retracted] Carnosol inhibits osteoclastogenesis in vivo and in vitro by blocking the RANKL‑induced NF‑κB signaling pathway. Epigenetic regulatory mechanism of macrophage polarization in diabetic wound healing (Review). Orphan nuclear receptor NR4A1 regulates both osteoblastogenesis and adipogenesis in human mesenchymal stem cells. [Retracted] MicroRNA‑519 enhances HL60 human acute myeloid leukemia cell line proliferation by reducing the expression level of RNA‑binding protein human antigen R.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1